Top Markets
#1 Siacoin Siacoin +36.43%
#2 DogBull DogBull +31.75%
#3 The Bitcoin Bull The Bitcoin Bull +26.25%
#4 Merlin's Seal BTC Merlin's Seal BTC +25.80%
#5 Cash Cat Cash Cat +21.04%
#6 Pons Pons +15.95%
#7 MarsCoin MarsCoin +14.68%
#8 Cryptopia Cryptopia +10.10%
#9 Akedo Akedo +7.80%
#10 Bonk Bonk +7.69%
Coin of the day
Siacoin Siacoin
Settings
Language
ENGLISH
Currency
USD
Theme
Egetis Therapeutics AB (publ) Egetis Therapeutics AB (publ)

Egetis Therapeutics AB (publ)

EGTX
Rank in Stocks #14551
Egetis Therapeutics AB (publ) is a pharmaceutical enterprise committed to... Egetis Therapeutics AB (publ) is a pharmaceutical enterprise committed to progressing drug development, primarily focusing on late-stage projects. The company's core mission involves addressing significant unmet medical needs within the orphan drug sector, concentrating on severe and rare or niche diseases. Its current therapeutic pipeline includes two key drugs undergoing Phase IIb/III clinical trials: Aladote, which is designed to mitigate the risk of acute liver damage associated with acetaminophen/paracetamol poisoning, and Emcitate, intended for the management of MCT8 deficiency, a rare congenital disorder impacting thyroid hormone signaling. Established in 2006, Egetis Therapeutics AB (publ) is headquartered in Stockholm, Sweden, and was previously known as PledPharma AB (publ) until its name change in December 2020.
Share Price
$0.87679425
Last synced: 2026-08-31
Market Cap
$407.66M
Change (1 day)
-1.88%
Change (1 year)
58.03%
Country
SE
Trade Egetis Therapeutics AB (publ) (EGTX)

Category

Healthcare
Revenue for Egetis Therapeutics AB (publ) (EGTX)
Revenue in Sep 2026 TTM: 0
According to Egetis Therapeutics AB (publ) latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Egetis Therapeutics AB (publ) from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH